These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16297806)

  • 1. Effects of conversion from cyclosporine to tacrolimus on left ventricular structure in cardiac allograft recipients.
    Peura JL; Zile MR; Feldman DS; VanBakel AB; McClure C; Uber W; Haynes H; Pereira NL
    J Heart Lung Transplant; 2005 Nov; 24(11):1969-72. PubMed ID: 16297806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact on biochemical profiles and allograft function for patients converted from cyclosporine to tacrolimus after clinical heart transplantation.
    Wang CH; Chou NK; Ko WJ; Chi NH; Tsao CI; Wang SS
    Transplant Proc; 2008 Oct; 40(8):2600-2. PubMed ID: 18929812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
    Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
    J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: a randomized clinical trial.
    Paoletti E; Cassottana P; Amidone M; Gherzi M; Rolla D; Cannella G
    Am J Kidney Dis; 2007 Jul; 50(1):133-42. PubMed ID: 17591533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus.
    White M; Ross H; Haddad H; LeBlanc MH; Racine N; Pflugfelder P; Giannetti N; Davies R; Azevedo E; Isaac D; Burton J; Ferguson R; Genest J
    Transplantation; 2006 Sep; 82(6):763-70. PubMed ID: 17006323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steroid withdrawal in living donor renal transplant recipients using tacrolimus and cyclosporine: a randomized prospective study.
    Park JB; Kim SJ; Oh HY; Han YS; Kim DJ; Park JW; Kwon CH; Joh JW; Lee SK
    Transpl Int; 2006 Jun; 19(6):478-84. PubMed ID: 16771869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation.
    Barten MJ; Garbade J; Bittner HB; Fiedler M; Dhein S; Thiery J; Mohr FW; Gummert JF
    Int Immunopharmacol; 2006 Dec; 6(13-14):2011-7. PubMed ID: 17161355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients.
    Naito T; Mino Y; Otsuka A; Ushiyama T; Ito T; Ozono S; Kagawa Y; Kawakami J
    J Clin Pharmacol; 2009 Jun; 49(6):710-8. PubMed ID: 19451405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
    Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
    Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion of cyclosporine to tacrolimus in stable renal allograft recipients: quantification of effects on the severity of gingival enlargement and hirsutism and patient-reported outcomes.
    Walker RG; Cottrell S; Sharp K; Tripodi R; Nicholls KM; Fraser I; Varigos GA; Butcher BE
    Nephrology (Carlton); 2007 Dec; 12(6):607-14. PubMed ID: 17995589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steroid-free immunosuppression in kidney transplant recipients and prograf monotherapy: an interim analysis of a prospective multicenter trial.
    Bäckman L; Aselius H; Lindberger K; Svensson L; Strömbom U; Olausson E; Hadimeri H; Deurell SI; Norrby J; Gäbel M; Ebermark A; Olausson M
    Transplant Proc; 2006 Oct; 38(8):2654-6. PubMed ID: 17098029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial.
    Meier M; Nitschke M; Weidtmann B; Jabs WJ; Wong W; Suefke S; Steinhoff J; Fricke L
    Transplantation; 2006 Apr; 81(7):1035-40. PubMed ID: 16612281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early conversion from cyclosporine to tacrolimus increases renal graft function in chronic allograft nephropathy at BANFF stages I and II.
    Marcard T; Ivens K; Grabensee B; Willers R; Helmchen U; Rump LC; Blume C
    Transpl Int; 2008 Dec; 21(12):1153-62. PubMed ID: 18684111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy.
    Tang SC; Chan KW; Tang CS; Lam MF; Leung CY; Tse KC; Li CS; Ho YW; Tong MK; Lai KN; Chan TM;
    Nephrol Dial Transplant; 2006 Nov; 21(11):3243-51. PubMed ID: 16877482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor.
    Brandhorst G; Tenderich G; Zittermann A; Oezpeker C; Koerfer R; Oellerich M; Armstrong VW
    Ther Drug Monit; 2008 Feb; 30(1):113-6. PubMed ID: 18223473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study.
    Marcén R; Chahin J; Alarcón A; Bravo J
    Transplant Proc; 2006 Oct; 38(8):2427-30. PubMed ID: 17097957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose metabolism before and after conversion from cyclosporine microemulsion to tacrolimus in stable renal recipients.
    Gelens MA; Christiaans MH; van Hooff JP
    Nephrol Dial Transplant; 2008 Feb; 23(2):701-6. PubMed ID: 17999993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus.
    Chamienia A; Biedunkiewicz B; Król E; Debska-Slizień A; Rutkowski B
    Transplant Proc; 2006; 38(1):81-5. PubMed ID: 16504670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.